ClinicalTrials.gg

Program

AZD1163

A development code.

Its studies are mostly in Arthritis, Rheumatoid, led by AstraZeneca.

Furthest: phase 2, since Dec 1, 20252 company-led studies, 1 open or runningNext primary completion: Nov 12, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca21 open or runningphase 2since Dec 1, 2025Oct 23, 2023Nov 12, 2027phase 2 · NCT07276581
  • Named in AstraZeneca’s own pipeline as AZD1163, phase 2, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2023First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06103877 · 108 enrolled · United States, Germany
  2. Dec 1, 2025Phase 2 study in Arthritis, RheumatoidPhase 2 reachedNCT07276581 · 320 planned · United States, Argentina, Brazil and more

Ahead

  1. Nov 12, 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07276581

TargetBeta

“AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular peptidyl arginine deiminase 2 (PAD2) and peptidyl arginine deiminase 4 (PAD4) enzymes, which are responsible for protein citrullination.”study text, read by Claude · the study

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07276581Arthritis, Rheumatoid · United States, Argentina, Brazil and more2RecruitingNov 12, 2027320
NCT06103877Arthritis, Rheumatoid · United States, Germany1CompletedJan 13, 2026108

How it is read

Names in the registry

  • “AZD1163”, 2 entries

Codes read as this program: AZD1163.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.